Business Context and Reporting Period
Company: Isis Pharmaceuticals, Inc. (Note: Filing text refers to "ISIS PHARMACEUTICALS, INC." despite metadata listing "IONIS PHARMACEUTICALS INC")
Reporting Period: Quarterly period ended September 30, 1999 (Form 10-Q)
Business Overview: A biopharmaceutical company focused on research, drug discovery, and development of antisense drugs. The company is not yet profitable and relies on collaborative research agreements, grants, and financing to fund operations. Key activities include the development of Vitravene (approved for CMV retinitis) and a joint venture with Elan Corporation (Orasense Ltd.) for oral drug delivery technology.
Key Financial Metrics
| Metric | Three Months Ended 9/30/99 | Nine Months Ended 9/30/99 | As of 9/30/99 |
|---|---|---|---|
| Total Revenue | $10.6 million | $24.4 million | N/A |
| Net Loss (Applicable to Common) | $(12.6) million | $(41.8) million | N/A |
| Net Loss Per Share (Basic/Diluted) | $(0.44) | $(1.49) | N/A |
| Operating Expenses | $18.7 million | $55.0 million | N/A |
| Cash and Cash Equivalents | N/A | N/A | $38.3 million |
| Short-term Investments | N/A | N/A | $5.5 million |
| Total Current Assets | N/A | N/A | $48.5 million |
| Total Current Liabilities | N/A | N/A | $17.6 million |
| Working Capital | N/A | N/A | $30.9 million |
| Long-term Debt (Carrying Value) | N/A | N/A | $89.7 million |
| Cash Used in Operations (9 months) | N/A | $(37.4) million | N/A |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased to $10.6 million for the quarter (from $19.3 million in Q3 1998) and $24.4 million for the nine months (from $31.0 million in 1998). This decrease is primarily attributed to the absence of two large one-time transactions in 1998: a $7.5 million milestone payment from CIBA Vision and a $4.0 million patent license fee to CpG ImmunoPharmaceuticals.
- Increased Losses: Net loss applicable to common stock widened to $12.6 million for the quarter (from $1.0 million in Q3 1998) and $41.8 million for the nine months (from $26.3 million in 1998). The Q3 1999 loss included a $2.0 million equity loss from the Orasense joint venture.
- Expense Trends: Research and development expenses remained relatively flat ($16.3 million vs. $16.5 million in Q3 1998). General and administrative expenses increased to $2.4 million (from $2.3 million) due to additional staffing and outside services.
- Interest Expense: Interest expense for the nine months increased to $8.4 million (from $6.8 million in 1998) due to $40 million in private debt financings finalized in 1998. Most of this interest is accrued and deferred for five years.
- Liquidity Position: Cash and short-term investments decreased to $43.9 million (from $58.8 million at year-end 1998) due to operating losses, capital expenditures, and the investment in the Orasense joint venture, partially offset by $27 million in equity proceeds.
Guidance, Outlook, and Risks
- Outlook: Management expects to continue operating losses for the next few years as R&D activities grow. The company believes existing cash, investments, and contract revenue will meet requirements for at least the next 18 months.
- Strategic Developments:
- Formed Orasense Ltd. joint venture with Elan Corporation for oral oligonucleotide drug delivery.
- Entered collaborations with Rhone-Poulenc Rorer (genomics target validation) and Abbott Laboratories (commercial manufacturing of ISIS 2302).
- Received EU marketing approval for Vitravene in August 1999.
- Year 2000 Issues: The company is nearing completion of remediation and testing. Estimated total cost is under $500,000. Primary risk exposure is dependence on commercial utilities (water/power) provided by third parties; failure could halt R&D for 3-6 months.
- Debt Obligations: Significant long-term debt ($89.7 million) includes $40 million in private loans with deferred principal and interest payments until 2002/2007. A line of credit with Boehringer Ingelheim had an outstanding balance of $22.6 million.
- Market Risk: The company does not use derivative instruments. Exposure to interest rate changes is limited to long-term debt and short-term investments.
Investor Verification Checklist
- Revenue Sustainability: Verify the timing and likelihood of future milestone payments and collaboration revenues to offset the decline from one-time 1998 transactions.
- Cash Burn Rate: Confirm the 18-month liquidity runway given the $37.4 million cash burn from operations in the first nine months of 1999.
- Joint Venture Impact: Assess the financial performance and strategic value of the Orasense joint venture, which contributed a $2.0 million equity loss in Q3 1999.
- Debt Maturity: Review the terms of the $40 million private debt and $22.6 million Boehringer Ingelheim line of credit, specifically regarding the 2002 and 2007 maturity dates and accrued interest obligations.
- Year 2000 Contingency: Evaluate the robustness of contingency plans regarding utility providers, as internal systems are largely remediated.